Coronavirus (COVID-19) Q&A Podcast Por JAMA Network arte de portada

Coronavirus (COVID-19) Q&A

Coronavirus (COVID-19) Q&A

De: JAMA Network
Escúchala gratis

Conversations with experts and frontline clinicians about the COVID-19 pandemic, hosted by editors from the JAMA Network.2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies. Ciencia Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections
    Sep 2 2025

    Interview with Robert Bals, MD, PhD, author of Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial, and Dan H. Barouch, MD, PhD, author of A Novel Approach for Preventing Respiratory Virus Infections. Hosted by Eve Rittenberg, MD.

    Related Content:

    • Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections
    • A Novel Approach for Preventing Respiratory Virus Infections
    Más Menos
    12 m
  • Association of New-Onset Seizures With SARS-CoV-2 Vaccines
    Apr 29 2024

    Interview with Churl-Su Kwon, MD, MPH, author of Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hosted by Cynthia E. Armand, MD.

    Related Content:

    • Association of New-Onset Seizures With SARS-CoV-2 Vaccines
    Más Menos
    17 m
  • Measuring Medicaid Enrollment More Accurately to Guide Post–COVID-19 Pandemic Policy
    Apr 5 2024

    Benjamin D. Sommers, MD, PhD, of Harvard University, speaks with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, about differences in Medicaid enrollment as measured in surveys and administrative data. These differences have implications for estimating coverage now that the federal policy of continuous Medicaid eligibility during the COVID-19 pandemic has ended.

    Related Content:

    • Survey-Reported Coverage in 2019-2022 and Implications for Unwinding Medicaid Continuous Eligibility
    Más Menos
    19 m
Todavía no hay opiniones